New interview with our CEO, giving a good overview of; - NYR's stage of development, - a quick summation of the recent, strongly supportive animal model data gathered prior to starting the current human study, and - where to from here.
In brief, for those newly interested; Data shows this drug's ability to block TRPC channels, (channels which play an integral role in cellular injury in the heart and brain). The three indications where the drug is showing 'significant protection';- stroke,- traumatic brain injury,- myocardial infarction/heart attack. We're now half way through our Phase 1, first in human study, with no issues.
Looking forward to coming instalments!
NYR Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)